Moreover, treatment with these inhibitors disrupts CRC cell adaptation to acidic stress by interfering with tumor acidity regulation, suggesting a novel acid-modulating role for anticancer drugs that target integrin, FAK, and STAT3. Here, PTK2 is linked to colorectal carcinoma.